SAN DIEGO–(BUSINESS WIRE)–Alterome Therapeutics, Inc., a clinical-stage precision oncology company focused on discovering and developing alteration-specific therapeutics to address oncogenic drivers, today announced the presentation of the preliminary clinical data from the Phase 1 dose-escalation portion of its ongoing Phase 1/1b clinical trial evaluating ALTA3263, an orally available KRAS-selective, pan-mutant, active/inactive (ON/OFF) inhibitor, in adult patients with KRAS-mutant advanced